STATEN
BIOTECHNOLOGY

Staten Biotechnology announces publication in Nature Medicine of pre-clinical data supporting the therapeutic potential of its antibody STT-5058 in management of dyslipidemia

21th, August 2017

Nijmegen, The Netherlands – Staten Biotechnology ("Staten"), a company focused on the treatment of dyslipidemia and reduction of cardiovascular mortality, today announced a publication in Nature Medicine of pre-clinical data, supporting the therapeutic potential of STT-5058 in dyslipidemia management.

Data co-generated by Staten's team and published by Prof. Dan Rader, Staten's co-founder and advisor and by Seymour Gray, Professor of Molecular Medicine at the University of Pennsylvania, indicates that Staten's antibody STT-5058 increases apoC3 clearance and lowers both triglycerides and triglyceride-rich lipoproteins (TRL) in mice expressing human *APOC3*. Genetic evidence supports that a missense variant in *APOC3* reduces triglycerides levels and protects from coronary heart disease. The STT-5058 antibody potentially offers a new therapeutic approach to reduce triglycerides and TRL and hence a protection mechanism against heart disease.

"The data published goes one step further in supporting the role of STT-5058 in apoC3 clearance and triglyceride lowering" commented Paul da Silva Jardine, Staten's CSO. "We have strong *in vivo* evidence that STT-5058, a pH-dependent recycling antibody, is able to clear significant amounts of apoC3. The abundance of apoC3 in the body has proven quite a challenge in the past when others attempted to develop similar antibodies. We are therefore very excited to advance this drug-candidate into the clinic.".

Staten has recently taken the STT-5058 program into formal pre-clinical development and is preparing to initiate the first-in-man study.

About ApoC3

ApoC3 is protein with several modes of action: it inhibits very-low-density-lipoproteins (VLDL) uptake by the liver and it inhibits the activity of lipoprotein lipase leading to high levels of lipoproteins and triglycerides. Loss of function mutations in ApoC3 leads to reduced incidence of vascular and heart diseases and are independent of LDL cholesterol levels. This supports the potential of the anti-ApoC3 antibody to act as key molecule in dyslipidemia management.

About Staten

Staten Biotechnology aims to develop novel and innovative strategies for the treatment of dyslipidemia, with a focus on the triglyceride space. Staten Biotechnology B.V. was incorporated in 2014 by world-leading experts in dyslipidemia, Paul da Silva Jardine, Daniel Rader and Alan Tall. Forbion Capital Partners and BioGeneration Ventures are its current investors.

STATEN
BIOTECHNOLOGY

For further information, please contact:
Daniela Couto
Managing Director
Staten Biotechnology B.V
+31-36-6993000
info@statenbiotech.com